elsulfavirine + sofosbuvir + daclatasvir

**elsulfavirine + sofosbuvir + daclatasvir** is an oral triple combination regimen of direct-acting antivirals and an NNRTI, envisioned for the treatment of chronic hepatitis C virus (HCV) infection and potentially HIV/HCV co-infection. **Sofosbuvir** is an NS5B RNA-dependent RNA polymerase inhibitor, **daclatasvir** is an NS5A replication complex inhibitor, and **elsulfavirine** is a non-nucleoside reverse transcriptase inhibitor (NNRTI) developed primarily as an antiretroviral for HIV. In combination, sofosbuvir and daclatasvir target different steps of HCV replication and are approved for HCV therapy; elsulfavirine is included to offer activity against HIV in co-infected patients, although its use in HCV therapy is not standard[1][2][3][5].